Form 4 for CUE Cue Biopharma, Inc.
Accepted 2026-05-07 16:00:05 ET · period of report 2026-05-03 · accession 0001193125-26-211806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-07 16:00 | 2026-05-03 | CUE | Lin Shao-Lee | CEO, Dir | A - Grant | $0.00 | +327.5K | 327.5K | New | $0 |
| D | 2026-05-07 16:00 | 2026-05-03 | CUE | Lin Shao-Lee | CEO, Dir | A - Grant | $0.00 | +655.1K | 655.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-03 | A | A | 327,537 | $0.00 | 327,537 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2026-05-03 | A | A | 655,074 | $0.00 | 655,074 | D | $30.42 · — to 2036-05-02 | 655,074 Common Stock | (F1) This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026. |